In two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2HBu8jJ